Cardiovascular Safety of JAK Inhibitors in Younger Adults With Rheumatoid Arthritis: A Propensity-Matched Real-World Analysis (ACR Convergence 2026) - Sep 8, 2026 - Abstract #2386; Pres time: Nov 10, 2026; 10:30 AM - 12:30 PM; Location: WB1&2; In Person; "Adults aged 18-64 years with RA initiating JAKi (tofacitinib, baricitinib, or upadacitinib) or TNFi (adalimumab, etanercept, infliximab, certolizumab pegol, or golimumab) between 2013 and 2024 were identified. In this large multinational real-world cohort of adults aged 18-64 years with RA, JAK inhibitors were not associated with increased risks of MACE or arterial cardiovascular events compared with TNF inhibitors. A modest trend toward increased VTE risk was observed, while expected metabolic effects were confirmed. These findings suggest that the cardiovascular safety signal identified in ORAL Surveillance may not be generalizable to younger, lower-risk RA populations and support individualized cardiovascular risk stratification when selecting targeted therapies."
Clinical • Real-world • Real-world evidence • Cardiovascular • Diabetes • Dyslipidemia • Hypertension • Immunology • Infectious Disease • Inflammatory Arthritis • Metabolic Disorders • Rheumatoid Arthritis • Rheumatology • Type 2 Diabetes Mellitus • Venous Thromboembolism
|
|
Deepak Lamichanne1; Madhumitha Rondla1; Eysha Mostafa1; Yagnapriya Chirrareddy1; Islam Hamza Zaki2; Bhaswanth Bollu1
|